News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Carl Icahn Quietly Reduces Stake in Allergan (AGN)



11/15/2016 7:31:14 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Allergan is a drug company with a strong drug pipeline and is cash-rich. So rich that it could really use a major acquisition to help juice growth. But the merger with Pfizer fell apart, and AGN has backed away from a major merger with the likes of Gilead and Biogen. Instead, the company is spending money on itself. Which isn't a bad investment, considering its share price is at the cheapest level we've seen in close to three years. As well, the political upheaval for biotechs has been overblown. The industry has tailwinds, thanks to the Donald Trump win. And it helps that AGN is a bit different, where its aesthetics business model is rather insulated from political risk.

Read at Seeking Alpha
Read at Wall Street Journal
Read at Reuters
Read at Bloomberg


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES